文献速递间质性肺疾病

三月FVC变化:基于个体参与者数据荟萃分析的特发性肺纤维化试验终点

Three-Month FVC Change: A Trial Endpoint for Idiopathic Pulmonary Fibrosis Based on Individual Participant Data Meta-analysis.
PubMed 文献 · Am J Respir Crit Care Med · 2022-01-01

该研究基于12个安慰剂队列共1819例IPF患者的个体数据,采用两步随机效应荟萃分析,评估基线或3个月时FVC、DLCO和6分钟步行距离变化与死亡或疾病进展的关联。结果显示3个月FVC相对下降2.5%与未治疗和已治疗患者死亡风险分别增加15%和20%相关,3个月FVC变化治疗效应在抗纤维化药物与安慰剂组间显著。3个月FVC变化可能作为IPF适应性试验的替代终点。

要点

  • 3个月FVC相对下降2.5%与未治疗IPF患者死亡风险增加15%相关。
  • 3个月FVC相对下降2.5%与已治疗IPF患者死亡风险增加20%相关。
  • 抗纤维化治疗与安慰剂组3个月FVC变化差异为42.9 ml(95%CI 24.0-61.8 ml,P<0.001)。

核心结论

  • 3个月生理变量变化尤其是FVC与IPF患者死亡相关,3个月FVC变化可能作为IPF适应性试验的替代终点。

研究设计与样本

  • 采用两步随机效应荟萃分析,纳入IPF临床试验的个体参与者数据,评估基线或3个月FVC、DLCO和6分钟步行距离变化与安慰剂组死亡或疾病进展的关联。
  • 安慰剂队列12个共1819例参与者,治疗数据来自6个队列共1684例参与者。

主要发现

  • 基线及3个月所有生理变量变化均独立与更差结局相关。
  • 3个月FVC相对下降每2.5%,未治疗者死亡调整风险比1.15(95%CI 1.06-1.24,I2=59.4%),已治疗者调整风险比1.20(95%CI 1.12-1.28,I2=18.0%)。
  • 治疗组与安慰剂组3个月FVC变化差异为42.9 ml(95%CI 24.0-61.8 ml,P<0.001)。

关键数值与推荐

  • 3个月FVC相对下降2.5%对应未治疗者死亡调整风险比1.15(95%CI 1.06-1.24)。
  • 3个月FVC相对下降2.5%对应已治疗者死亡调整风险比1.20(95%CI 1.12-1.28)。
  • 抗纤维化治疗与安慰剂3个月FVC变化差异42.9 ml(95%CI 24.0-61.8 ml,P<0.001)。

临床怎么用

  • 在IPF早期和适应性试验中,可考虑将3个月FVC变化作为加速评估的候选替代终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Novel therapies for idiopathic pulmonary fibrosis (IPF) are in development, but there remains uncertainty about the optimal trial endpoint. An earlier endpoint would enable assessment of a greater number of therapies in adaptive trial designs. Objectives: To determine whether short-term changes in FVC, DlCO, and six-minute-walk distance could act as surrogate endpoints to accelerate early-phase trials in IPF. Methods: Individual participant data (IPD) from IPF clinical trials were included in a two-step random-effects meta-analysis to determine whether baseline or 3-month changes in FVC, DlCO, and 6-minute-walk distance were associated with mortality or disease progression in placebo arms. Three-month and 12-month FVC decline endpoints were compared with treatment arm data from antifibrotic studies by meta-regression. Measurements and Main Results: IPD were available from 12 placebo cohorts totaling 1,819 participants, with baseline and 3-month changes in all physiological variables independently associated with poorer outcomes. Treatment data were available from six cohorts with 1,684 participants. For each 2.5% relative decline in FVC over 3 months, there was an associated 15% (adjusted hazard ratio, 1.15; 95% confidence interval [CI], 1.06-1.24; I2 = 59.4%) and 20% (adjusted hazard ratio, 1.20; 95% CI, 1.12-1.28; I2 = 18.0%) increased risk for mortality in untreated and treated individuals, respectively. An FVC change treatment effect was observed between treatment and placebo arms at 3 months (difference in FVC change of 42.9 ml; 95% CI, 24.0-61.8 ml; P < 0.001). Conclusions: IPD meta-analysis demonstrated that 3-month changes in physiological variables, particularly FVC, were associated with mortality among individuals with IPF. FVC change over 3 months may hold potential as a surrogate endpoint in IPF adaptive trials.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Khan FA, Stewart I, Moss S, et al. Three-Month FVC Change: A Trial Endpoint for Idiopathic Pulmonary Fibrosis Based on Individual Participant Data Meta-analysis. Am J Respir Crit Care Med. 2022. PMID: 35020580. doi:10.1164/rccm.202109-2091OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。